Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: Immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Savonenko, Alena V ^a   Melnikova, Tatiana ^a   Wang, Yuchuan ^a   Ravert, Hayden ^a   Gao, Yongjun ^a   Koppel, Jeremy ^b   Lee, Deidre ^a   Pletnikova, Olga ^a   Cho, Eugenia ^a   Sayyida, Nuzhat ^a   Hiatt, Andrew ^c   Troncoso, Juan ^a   Davies, Peter ^b   Dannals, Robert F ^a   Pomper, Martin G ^a   Horti, Andrew G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Neurology Johns Hopkins University School of Medicine ^*  (United States)

^c Mapp Biopharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CD68 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN ANTIBODY; TRACER; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELLULAR DISTRIBUTION; COMPUTED TOMOGRAPHY SCANNER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; GLIA CELL; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; SYNAPSE; ANIMAL; C57BL MOUSE; DIAGNOSTIC IMAGING; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; MICROGLIA; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALIA; MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, CANNABINOID, CB2;

EID: 84939186864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129618     Document Type: Article

References (81)

1. Budson AE, Solomon PR. New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician. Neurologist. 2012;18(6):356-63. doi: 10.1097/NRL 0b013e31826a998d PMID: 23114667.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44. PMID: 6610841.
3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005 PMID: 21514250; PubMed Central PMCID: PMC3312024.
4. Morris GH, Nagy Z. Alzheimer's disease. In: Esiri MM, Lee VM-Y, Trojanowsky JQ, editors. The Neuropathology of Dementia. 2nded. UK: Cambridge University Press; 2004.
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003 PMID: 21514248; PubMed Central PMCID: PMC3220946.
6. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N EnglJ Med. 2012;367(9):795-804. doi: 10. 1056/NEJMoa1202753 PMID: 22784036; PubMed Central PMCID: PMC3474597.
7. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451(7179):720-4. doi: 10.1038/nature06616 PMID: 18256671; PubMed Central PMCID: PMC3264491.
8. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb PerspectMed. 2012;2(1):a006346. doi: 10.1101/cshperspect. a006346 PMID: 22315714; PubMed Central PMCID: PMC3253025.
9. Lucin KM, O'Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron. 2013;79(5):873-86. doi: 10.1016/j.neuron. 2013.06.046 PMID: 24012002; PubMed Central PMCID: PMC3779465.
10. Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2008;153(2):277-85. doi: 10.1038/sj.bjp. 0707505 PMID: 17934510; PubMed Central PMCID: PMC2219537.
11. Ruiz-Valdepenas L, Benito C, Tolon RM, Martinez Orgado JA, Romero J. The endocannabinoid system and amyloid-related diseases. Exp Neurol. 2010;224(1):66-73. doi: 10.1016/j.expneurol.2010.03.024 PMID: 20353781.
12. Horti AG, Raymont V, Terry GE. Radioligands for imaging of cannabinoid system. In: Dierckx RA, Paans AMJ, de Vries EFJ, A. W, editors. PET and SPECTof Neurobiological Systems. Berlin Heidelberg Springer-Verlag; 2014, p. 249-320
13. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience. 2014. doi: 10.1016/j.neuroscience.2014.09. 061 PMID: 25286385.
14. Evens N, Vandeputte C, Coolen C, Janssen P, Sciot R, Baekelandt V, et al. Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer. Nucl Med Biol. 2012;39(3):389-99. doi: 10. 1016/j.nucmedbio.2011.09.005 PMID: 22154685.
15. Evens N, Vandeputte C, Muccioli GG, Lambert DM, Baekelandt V, Verbruggen AM, et al. Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorg MedChem. 2011;19(15):4499-505. doi: 10.1016/j.bmc.2011.06.033 PMID: 21737287.
16. Vandeputte C, Evens N, Toelen J, Deroose CM, Bosier B, Ibrahimi A, et al. A PET brain reporter gene system based on type 2 cannabinoid receptors. J Nucl Med. 2011;52(7):1102-9. doi: 10.2967/jnumed. 110.084426 PMID: 21680683.
17. Ahmad R, Koole M, Evens N, Serdons K, Verbruggen A, Bormans G, et al. Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40in healthy subjects. Mol Imaging Biol. 2013;15(4):384-90. doi: 10.1007/s11307-013-0626-y PMID: 23508466.
18. Postnov A, Ahmad R, Evens N. Quantification of 11C-NE40, a novel PET radioligand for CB2 receptor imaging. J Nucl Med. 2013;54(Suppl 2):188.
19. Hortala L, Arnaud J, Roux P, Oustric D, Oury-Donat F, Avenet P, et al. Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor. Bioorg Med Chem Lett. 2013. doi: 10.1016/j.bmcl.2013.11.023 PMID: 24291040.
20. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2, 2, 3, 3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4, 5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther. 2009;328(1):141-51. doi: 10.1124/jpet.108.145011 PMID: 18931146.
21. Horti AG, Gao Y, Ravert HT, Finley P, Valentine H, Wong DF, et al. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem. 2010;18(14):5202-7. doi: 10.1016/j.bmc.2010.05.058 PMID: 20554448; PubMed Central PMCID: PMC2903661.
22. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55(5):453-62. doi: 10.1002/glia.20467 PMID: 17203472; PubMed Central PMCID: PMC2871685.
23. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gammasecretase. Hum Mol Genet. 2004;13(2):159-70. doi: 10.1093/hmg/ddh019 PMID: 14645205.
24. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17(6):157-65. PMID:11337275.
25. Mukhopadhyay S, Das S, Williams EA, Moore D, Jones JD, Zahm DS, et al. Lipopolysaccharideand cyclic AMP regulation of CB (2) cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages. J Neuroimmunol. 2006;181(1-2):82-92. doi: 10.1016/j.jneuroim.2006.08.002 PMID: 17045344.
26. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003;23(35):11136-41. PMID: 14657172.
27. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050-8. PMID: 10818140.
28. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(6):3228-33. PMID: 10077666; PubMed Central PMCID: PMC15924.
29. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19(4):939-45. PMID: 9354339.
30. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in atransgenic mouse model of Alzheimer's disease. J Neurosci. 2008;28(51):13805-14. doi: 10.1523/JNEUROSCI.4218-08.2008 PMID: 19091971.
31. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiology of disease. 2005;18(3):602-17. Epub2005/03/10. doi: 10.1016/j.nbd.2004.10.022 PMID: 15755686.
32. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69(2):203-13. doi: 10.1016/j.neuron. 2011.01.002 PMID: 21262461; PubMed Central PMCID: PMC3058906.
33. Durand D, Carniglia L, Beauquis J, Caruso C, Saravia F, Lasaga M. Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor protein cleavage. Neuropharmacology. 2014;79:180-9. doi: 10.1016/j.neuropharm.2013.11.015 PMID: 24291464.
34. Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience. 2006;141(3):1149-62. doi: 10.1016/j.neuroscience.2006.05.001 PMID: 16753269.
35. Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, et al. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer's disease. Mol Neurodegener. 2011;6:45. doi: 10.1186/1750-1326-6-45 PMID: 21718498; PubMed Central PMCID: PMC3149591.
36. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(25):10601-6. doi: 10.1073/pnas. 0701096104 PMID: 17563384; PubMed Central PMCID: PMC1890560.
37. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005;64(9):743-53. PMID: 16141783.
38. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB (2) receptor. Eur J Pharmacol. 2000;396(2-3):141-9. PMID: 10822068.
39. Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci. 2013;33(9):3765-79. doi: 10.1523/JNEUROSCI.4251-12.2013 PMID: 23447589; PubMed Central PMCID: PMC3711622.
40. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci. 2008;1139:434-49. doi: 10.1196/annals.1432.036 PMID: 18991891.
41. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329-32. doi: 10.1126/science.1115740 PMID: 16224028.
42. Cecyre B, Thomas S, Ptito M, Casanova C, Bouchard JF. Evaluation of the specificity of antibodies raised against cannabinoid receptortype 2 in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(2):175-84. doi: 10.1007/s00210-013-0930-8 PMID: 24185999.
43. Marchalant Y, Brownjohn PW, Bonnet A, Kleffmann T, Ashton JC. Validating Antibodies to the Cannabinoid CB2 Receptor: Antibody Sensitivity Is Not Evidence of Antibody Specificity. J Histochem Cytochem. 2014;62(6):395-404. doi: 10.1369/0022155414530995 PMID: 24670796.
44. Dowie MJ, Grimsey NL, Hoffman T, Faull RL, Glass M. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. J Chem Neuroanat. 2014. doi: 10.1016/j.jchemneu.2014.06.004 PMID: 24978314.
45. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676-82. doi: 10.1038/nmeth.2019 PMID: 22743772.
46. Wang Y, Seidel J, Tsui BM, Vaquero JJ, Pomper MG. Performance evaluation of the GE healthcare eX-plore VISTA dual-ring small-animal PET scanner. J Nucl Med. 2006;47(11):1891-900. PMID: 17079824.
47. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptorforcannabinoids. Nature. 1993;365(6441):61-5. doi: 10.1038/365061a0 PMID: 7689702.
48. Ma Y, Hof PR, Grant SC, Blackband SJ, Bennett R, Slatest L, et al. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience. 2005;135(4):1203-15. doi: 10.1016/j.neuroscience.2005.07.014 PMID: 16165303.
49. Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage. 2007;38(1):34-42. doi: 10.1016/j.neuroimage. 2007.06.032 PMID: 17707126; PubMed Central PMCID: PMC2084071.
50. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006;1071(1):10-23. doi: 10.1016/j.brainres. 2005.11.035 PMID: 16472786.
51. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160(3):467-79. doi: 10.1111/j.1476-5381.2010.00729.x PMID: 20590558; PubMed Central PMCID: PMC2931549.
52. Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(46):E5007-15. doi: 10.1073/pnas. 1413210111 PMID: 25368177; PubMed Central PMCID: PMC4246322.
53. den Boon FS, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S, et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(9):3534-9. doi: 10.1073/pnas.1118167109 PMID: 22331871; PubMed Central PMCID: PMC3295302.
54. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol ExpTher. 1994;268(3):1612-23. PMID: 8138973.
55. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54-61. PMID: 7556170.
56. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000;108(1-2):169-90. PMID: 11106790.
57. Sugiura T, Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids. 2000;108(1-2):89-106. PMID: 11106784.
58. Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J. Glial expression of cannabinoid CB (2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience. 2008;151(1):104-10. doi: 10.1016/j.neuroscience.2007.10.029 PMID: 18068305.
59. Graeber MB, Streit WJ, Kiefer R, Schoen SW, Kreutzberg GW. New expression of myelomonocytic antigens by microglia and perivascular cells following lethal motor neuron injury. J Neuroimmunol. 1990;27(2-3):121-32. PMID: 2332482.
60. Tomita M, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T. Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. Hepatology. 1994;20(2):317-25. PMID: 7519162.
61. Sierra A, Abiega O, Shahraz A, Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci. 2013;7:6. doi: 10.3389/fncel.2013.00006 PMID: 23386811; PubMed Central PMCID: PMC3558702.
62. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, et al. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol ExpTher. 2007;322(3):1144-52. doi: 10.1124/jpet.107.121566 PMID: 17545311.
63. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 2005;49(2):211-9. doi: 10.1002/glia.20108 PMID: 15390091.
64. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol. 1999;126(3):665-72. doi: 10.1038/sj.bjp. 0702351 PMID: 10188977; PubMed Central PMCID: PMC1565857.
65. Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci. 2005;25(21):5217-24. doi: 10.1523/JNEUROSCI.5080-04.2005 PMID: 15917461.
66. Perez SE, Berg BM, Moore KA, He B, Counts SE, Fritz JJ, et al. DHAdiet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res. 2010;88(5):1026-40. doi: 10.1002/jnr.22266 PMID: 19859965; PubMed Central PMCID: PMC3118087.
67. Sepulveda-Falla D, Barrera-Ocampo A, Hagel C, Korwitz A, Vinueza-Veloz MF, Zhou K, et al. Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. J Clin Invest. 2014;124(4):1552-67. doi: 10.1172/JCI66407 PMID: 24569455; PubMed Central PMCID: PMC3973081.
68. Sepulveda-Falla D, Glatzel M, Lopera F. Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation. J Alzheimers Dis. 2012;32(1):1-12. doi: 10.3233/JAD-2012-120907 PMID: 22766738.
69. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153(2):240-51. doi: 10.1038/sj.bjp. 0707584 PMID: 18037916; PubMed Central PMCID: PMC2219530.
70. Ashton JC. Cannabinoids for the treatment of inflammation. CurrOpin Investig Drugs. 2007;8(5):373-84. PMID: 17520866.
71. Tolon RM, Nunez E, Pazos MR, Benito C, Castillo AI, Martinez-Orgado JA, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009;1283:148-54. doi: 10.1016/j.brainres.2009.05.098 PMID: 19505450.
72. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575-80. PMID: 8398148.
73. Mufson EJ, Benzing WC, Cole GM, Wang H, Emerich DF, Sladek JR Jr., et al. Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization with amyloid plaques. Neurobiology of aging. 1994;15(5):621-7. PMID: 7824054.
74. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3(1):16-32. doi: 10.1006/nbdi.1996.0003 PMID: 9173910.
75. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, et al. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature. 2011;472(7344):471-5. doi: 10.1038/nature10071 PMID: 21525931; PubMed Central PMCID: PMC3084546.
76. Underhill DM, Goodridge HS. Information processing during phagocytosis. Nat Rev Immunol. 2012;12(7):492-502. doi: 10.1038/nri3244 PMID: 22699831.
77. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation. 2005;2:29. doi: 10.1186/1742-2094-2-29 PMID: 16343349; PubMed Central PMCID: PMC1352348.
78. Aso E, Juves S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. J Alzheimers Dis. 2013;35(4):847-58. doi: 10.3233/JAD-130137 PMID: 23515018.
79. Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:8. doi: 10.1186/1742-2094-9-8 PMID: 22248049; PubMed Central PMCID: PMC3292807.
80. Koppel J, Vingtdeux V, Marambaud P, D'Abramo C, Jimenez H, Stauber M, et al. CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. Mol Med. 2013;19:357-64. doi: 10.2119/molmed.2013.00140 PMID: 24408112; PubMed Central PMCID: PMC3883962.
81. Schmole AC, Lundt R, Ternes S, Albayram O, Ulas T, Schultze JL, et al. Cannabinoid receptor2deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiology of aging. 2015;36(2):710-9. doi: 10.1016/j.neurobiolaging.2014.09.019 PMID: 25443294.